After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
BTAI belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of BioXcel Therapeutics Inc is $71.62M. A total of 6.96 million shares were traded on the day, compared to an average of 8.04M shares.
In the most recent transaction, O’Neill Vincent sold 165 shares of BTAI for 0.35 per share on Dec 16 ’24. After the transaction, the insider now owns 19,957 company shares. In a previous transaction on Dec 16 ’24, Mehta Vimal sold 3,117 shares at 0.36 per share. BTAI shares that CEO and President owns now total 59,605.
Among the insiders who sold shares, Steinhart Richard I disposed of 577 shares on Dec 16 ’24 at a per-share price of $0.36. This resulted in the Chief Financial Officer holding 20,932 shares of BTAI after the transaction. In another insider transaction, Rodriguez Javier sold 430 shares at $0.36 per share on Dec 16 ’24. Company shares held by the insider now total 24,423.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, BTAI has a high of $13.36 and a low of $1.17.
As of this writing, BTAI has an earnings estimate of -$1.13 per share for the current quarter. EPS was calculated based on a consensus of 3.0 estimates, with a high estimate of -$0.62 per share and a lower estimate of -$1.54. The company reported an EPS of -$5.12 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. BTAI’s latest balance sheet shows that the firm has $232.97M in Cash & Short Term Investments as of fiscal 2021. There were $1.10M in debt and $16.67M in liabilities at the time. Its Book Value Per Share was -$16.26, while its Total Shareholder’s Equity was $221.67M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BTAI is Buy with a score of 4.17.
